EHA 2024: Updates in the Treatment of CLL - Episode 17
The panel explores potential applications and impact of BTK inhibitor degraders as an emerging class of novel agents for treating relapsed/refractory chronic lymphocytic leukemia.
Video content above is prompted by the following: